Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 7Oropharyngeal Neoplasms 5Mesothelioma, Malignant 4Lung Neoplasms 4Laryngeal Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Mouth Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Salivary Gland Neoplasms 2Paranasal Sinus Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Medulloblastoma 2Lymphoid Interstitial Pneumonia 2Gallbladder Neoplasms 2Carcinoma 2Vaginal Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Solitary Fibrous Tumor, Pleural 1Sinonasal undifferentiated carcinoma 1Prostatic Neoplasms 1Penile Neoplasms 1PRETEXT I Hepatoblastoma 1Lymphatic Metastasis 1Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified 1

Interventions

Cisplatin 11Gemcitabine 10Radiotherapy, Intensity-Modulated 6Capecitabine 6Drug Therapy 3Docetaxel 3toripalimab 2spartalizumab 2pembrolizumab 2nimotuzumab 2fludarabine 2atezolizumab 2Specimen Handling 2Platinum 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fluorouracil 2Disulfides 2Cyclophosphamide 2Carboplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2tislelizumab 1sintilimab 1penpulimab 1olaparib 1fludarabine phosphate 1dehydroftorafur 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Nasopharyngeal Carcinoma × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡